Zobrazeno 1 - 10 of 58 pro vyhledávání: '"Rachel L, West"'
1
Akademický článek
Health State Questionnaires Deployed in Ulcerative Colitis Patients: The Medical, Psychological, and Economic Perspective
Autor: Damien S.E. Broekharst, Pepijn W.A. Thomas, Maurice G.V.M. Russel, Rachel L. West, Jeroen M. Jansen, Sjaak Bloem, Tessa E.H. Römkens
Publikováno v: Gastro Hep Advances, Vol 2, Iss 6, Pp 770-777 (2023)
Background and Aims: To determine how the health state of ulcerative colitis patients is impacted by their disease, different health state questionnaires are deployed. This study examines to what extent these health state questionnaires determine the
Externí odkaz: https://doaj.org/article/e75e42b07b2141cd8087329b6e456265
Zobrazit plný text záznamu
2
Akademický článek
Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options
Autor: Arno R. Bourgonje, Reinier C. A. van Linschoten, Rachel L. West, Maarten A. van Dijk, Coretta C. van Leer-Buter, Gursah Kats-Ugurlu, Marieke J. Pierik, Eleonora A. M. Festen, Rinse K. Weersma, Gerard Dijkstra
Publikováno v: Therapeutic Advances in Gastroenterology, Vol 14 (2021)
In the wake of the coronavirus disease 2019 (COVID-19) pandemic, it is unclear how asymptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected patients who present with acute severe ulcerative colitis (UC) can be treated effect
Externí odkaz: https://doaj.org/article/3df5814880f04332a481288eabae23b4
Zobrazit plný text záznamu
3
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
Autor: Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Löwenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. van der Meulen‐de Jong, Marjolijn Duijvestein
Publikováno v: Alimentary Pharmacology & Therapeutics, 57, 1, pp. 117-126
Alimentary Pharmacology & Therapeutics, 57, 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell
Straatmijer, T, van Schaik, F D M, Bodelier, A G L, Visschedijk, M, de Vries, A C, Ponsioen, C Y, Pierik, M, van Bodegraven, A A, West, R L, de Boer, N K H, Srivastava, N, Romkens, T E H, Hoekstra, J, Oldenburg, B, Dijkstra, G, van der Woude, J C, Löwenberg, M, Mujagic, Z, Biemans, V B C, van der Meulen-de Jong, A E & Duijvestein, M 2023, ' Effectiveness and safety of tofacitinib for ulcerative colitis : two-year results of the ICC Registry ', Alimentary Pharmacology and Therapeutics, vol. 57, no. 1, pp. 117-126 . https://doi.org/10.1111/apt.17248
Alimentary Pharmacology & Therapeutics, 57(1), 117-126. Wiley
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. WILEY
Contains fulltext : 290620.pdf (Publisher’s version ) (Open Access) BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8627fcaccc449fd1031dddee12b17e7
https://doi.org/10.1111/apt.17248
Zobrazit plný text záznamu
4
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial
Autor: Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch
Publikováno v: Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.
Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4a13f67ca392c8811058105e50cf3a
https://repository.ubn.ru.nl/handle/2066/293716
Zobrazit plný text záznamu
5
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents
Autor: Jan A. Hazelzet, Désirée van Noord, C. Janneke van der Woude, Christa D. Niehot, Reinier Cornelis Anthonius van Linschoten, Elyke Visser, Rachel L. West
Publikováno v: Alimentary Pharmacology & Therapeutics
Summary Background Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health policy makers worldwide. Aim To assess the cost of illness of IBD from the societal perspective taking into account time trends and geogra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448206a4a3bc0c574984cdb7ba1b3aad
https://doi.org/10.1111/apt.16445
Zobrazit plný text záznamu
6
Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
Autor: P W Jeroen Maljaars, Marijn C. Visschedijk, Tessa Straatmijer, Cyriel Y. Ponsioen, Marjolijn Duijvestein, Bas Oldenburg, Annemarie C. de Vries, Jeoffrey J L Haans, Frank Hoentjen, Nanne K. H. de Boer, C. Janneke van der Woude, Alexander Bodelier, Gerard Dijkstra, Vince B. C. Biemans, Willemijn A van Dop, Marieke Pierik, Jeroen M. Jansen, Sander van der Marel, Andrea E. van der Meulen-de Jong, Rachel L. West
Publikováno v: Journal of Crohn's and Colitis, 15(11), 1920-1930. Elsevier
Journal of Crohn's and Colitis, 15(11), 1920-1930. OXFORD UNIV PRESS
Journal of Crohn's & Colitis, 15(11), 1920-1930. Oxford University Press
Journal of Crohn's and Colitis, 15, 1920-1930
Journal of Crohn's and Colitis, 15(11), 1920-1930. Oxford University Press
Straatmijer, T, Biemans, V B C, Hoentjen, F, de Boer, N K H, Bodelier, A G L, Dijkstra, G, van Dop, W A, Haans, J J L, Jansen, J M, Maljaars, P W J, van der Marel, S, Oldenburg, B, Ponsioen, C Y, Visschedijk, M C, de Vries, A C, West, R L, van der Woude, C J, Pierik, M, Duijvestein, M & van der Meulen-de Jong, A E 2021, ' Ustekinuma b for Crohn's Disease : Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study ', Journal of Crohn's and Colitis, vol. 15, no. 11, pp. 1920-1930 . https://doi.org/10.1093/ecco-jcc/jjab081
Journal of Crohn's and Colitis, 15, 11, pp. 1920-1930
Aims Ustekinumab is a monoclonal antibody that selectively targets p40, a shared subunit of the cytokines interleukin [IL]-12 and IL-23. It is registered for the treatment of inflammatory bowel diseases. We assessed the 2-year effectiveness and safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3636bc215f49fbd01878e2c877734f6b
https://doi.org/10.1093/ecco-jcc/jjab081
Zobrazit plný text záznamu
7
Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients
Autor: Rinse K. Weersma, Arno R. Bourgonje, Reinier Cornelis Anthonius van Linschoten, Gerard Dijkstra, Gursah Kats-Ugurlu, Maarten A van Dijk, Eleonora A. M. Festen, Marieke Pierik, Coretta Van Leer-Buter, Rachel L. West
Publikováno v: Therapeutic Advances in Gastroenterology, 14, 1-11. SAGE Publications Inc.
Therapeutic advances in gastroenterology, 14. SAGE Publications Inc.
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
In the wake of the coronavirus disease 2019 (COVID-19) pandemic, it is unclear how asymptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected patients who present with acute severe ulcerative colitis (UC) can be treated effect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a74aebcd4e6154c686aafd48c81fa8c
https://cris.maastrichtuniversity.nl/en/publications/ebb495d4-4b52-486a-b7e7-ff81e25e44ac
Zobrazit plný text záznamu
8
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial
Autor: Jan van den Brande, Tessa Uiterwaal, Christianne J. Buskens, Juda Vecht, Robert E G J M Pierik, Job H.C. Peters, Nofel Mahmmod, John Maring, E. Joline de Groof, Toer W. Stevens, H. B. A. C. Stockmann, Pieter C. F. Stokkers, Karlien F. Bruin, Eric J. Hazebroek, Ailsa Hart, Arnold van de Laar, Hubert A Prins, Richard van Hillegersberg, Rachel L. West, Paul Kingma, Menno A. Brink, Pritesh Morar, Ruud Schouten, Marno C.M. Rijk, A Jeroen de Groof, Sijbrand Hofker, Annekatrien Depla, Bregje Mol, Janneke van der Woude, T. J. Gardenbroek, Janindra Warusavitarne, Bas Oldenburg, Edwin S. van der Zaag, Anna A. W. van Geloven, Rogier M P H Crolla, Emma J. Eshuis, Hans Brouwer, Meindert N. Sosef, Maria L Haasnoot, Geert R. D'Haens, Nynke Talstra, Marcel Spanier, Liekele Oostenbrug, Jeroen M. Jansen, Maarten J Boom, Donald L. van der Peet, Nanne K. H. de Boer, Willem A. Bemelman, Cyriel Y. Ponsioen, Rosalie C Mallant, Theo J.M. van Ditzhuijsen, Gerard Dijkstra, Alexander P.J. Houdijk, Willem A. Marsman, Djuna Cahen, Casper G. Noomen, Huib A. Cense, Esther C. J. Consten, Michael F. Gerhards, Ad A. van Bodegraven, Rob J. Lieverse, Andreas Marinelli, Sjoerd van der Werff, Clemens Bolwerk, Ernst Jan Spillenaar Bilgen, Quirijn A. J. Eijsbouts, Guido Mannaerts, Bart A. van Wagensveld
Publikováno v: The lancet. Gastroenterology & hepatology, 5(10), 900-907. HANLEY & BELFUS-ELSEVIER INC
LIR!C study group 2020, ' Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease : retrospective long-term follow-up of the LIR!C trial ', The Lancet Gastroenterology and Hepatology, vol. 5, no. 10, pp. 900-907 . https://doi.org/10.1016/S2468-1253(20)30117-5
The Lancet Gastroenterology and Hepatology, 5(10), 900-907. Elsevier Ltd
lancet. Gastroenterology & hepatology, 5(10), 900-907. Elsevier Limited
BACKGROUND: The LIR!C trial showed that laparoscopic ileocaecal resection is a cost-effective treatment that has similar quality-of-life outcomes to treatment with infliximab, an anti-tumour necrosis factor (TNF) drug. We aimed to compare long-term o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e5752a7757a14a7ceff01b5b9c7a95a
https://doi.org/10.1016/s2468-1253(20)30117-5
Zobrazit plný text záznamu
9
Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients
Autor: B van Ruijven, Frank Hoentjen, Tessa E H Römkens, Jeroen M. Jansen, Rachel L. West, M E de Jong, Lisa J T Smits, N. Den Broeder, Maurice G. Russel
Publikováno v: Journal of Crohn's and Colitis, 14, 7, pp. 888-895
Journal of Crohn's and Colitis, 14, 888-895
Background and Aims There is paucity of data on safety and efficacy of anti-tumour necrosis factor [TNF] in elderly inflammatory bowel disease [IBD] patients. We aimed to compare the long-term treatment failure rates and safety of a first anti-TNF ag
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a38bc7c367921353502898d293373a
https://doi.org/10.1093/ecco-jcc/jjaa012
Zobrazit plný text záznamu
10
De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
Autor: Pepijn W A, Thomas, Lisa J T, Smits, Maarten, Te Groen, Rachel L, West, Maurice G V M, Russel, Jeroen M, Jansen, Tessa E H, Römkens, Frank, Hoentjen
Publikováno v: European Journal of Gastroenterology & Hepatology, 34, 5, pp. 488-495
European Journal of Gastroenterology & Hepatology, 34, 488-495
Limited data are available on biological therapy de-escalation after prior escalation in inflammatory bowel disease (IBD) patients. This study aimed to assess the frequency and success rate of de-escalation of biological therapy in IBD patients after
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192a4656261c4ec5823ed3babe5a4edf
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje